June 12, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Compared with placebo, semaglutide was associated with improved quality of life outcomes for patients with type 2 diabetes and chronic kidney disease. Study data were presented at the European Renal Association Congress in Glasgow, Scotland.
June 12, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

GLASGOW, Scotland, June 4, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63rd ERA Congress,…

Once-weekly injectable semaglutide 2.4 mg was linked to reductions in body weight and improvements in multiple cardiometabolic…

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more…

NEW ORLEANS —A once-weekly combination therapy of cagrilintide and semaglutide reduced HbA1c and body weight across a wide range…

Once-weekly injectable semaglutide is tied to weight loss and cardiovascular benefits for women regardless of menopause status,…

Christopher Lock, MD, spoke with Healio about findings from the Evoke and Evoke+ trials presented at the 2026 American Academy of…